Thoratec Expands Circulatory Support Biz With Levitronix Acquisition
This article was originally published in The Gray Sheet
Executive Summary
Thoratec will broaden its mechanical circulatory support portfolio through the purchase of Levitronix’s acute surgical support offerings for up to $150 million.
You may also be interested in...
Thoratec Goes Back To The Future With CEO Appointment
D. Keith Grossman, who led the LVAD maker from 1996 to 2006, has returned as CEO following the resignation of Gary Burbach. The company has been reporting declining sales of its franchise HeartMate II LVAD system.
Destination Therapy HeartMate II Implants Drives Thoratec’s Fast Growth
“Looking forward, we anticipate that the DT indication will continue to drive growth across the spectrum of centers, but with an increasingly important contribution from smaller transplant and open heart centers,” CEO Gerhard Burbach said.
Thoretec Pipeline: HeartMate III Fully Magnetic LVAD Trial Set For 2012
Thoratec plans to start a clinical trial at the end of 2012 for its next-generation HeartMate III left ventricular assist device with a magnetically levitated rotor designed to help reduce the risk of pump-related clots, bleeding and strokes.